economic evaluation of first-line treatments for metastatic renal cell carcinoma a cost-effectiveness analysis in a health resource–limited setting经济评价的一线治疗转移性肾细胞癌在卫生资源有限的环境成本效益分析.pdfVIP

Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting 1 2 3 4 1 1 2 Bin Wu , Baijun Dong , Yuejuan Xu , Qiang Zhang , Jinfang Shen , Huafeng Chen , Wei Xue * 1 Clinical Outcomes and Economics Group, Department of pharmacy, Renji Hospital, affiliated with the School of Medicine, Shanghai Jiaotong University, Shanghai, People’s Republic of China, 2 Department of Urology, Renji Hospital, affiliated with the School of Medicine, Shanghai Jiaotong University, Shanghai, People’s Republic of China, 3 Department of Oncology, the Second Hospital of Nanjing, affiliated to Medical School of South East University, Nanjing, People’s Republic of China, 4 Department of Oncology, Shanghai Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China Abstract Background: To estimate, from the perspective of the Chinese healthcare system, the economic outcomes of five different first-line strategies among patients with metastatic renal cell carcinoma (mRCC). Methods and Findings: A decision-analytic model was developed to simulate the lifetime disease course associated with renal cell carcinoma. The health and economic outcomes of five first-line strategies (interferon-alfa, interleukin-2, interleukin-2 plus interferon-alfa, sunitinib and bevacizumab plus interferon-alfa) were estimated and assessed by indirect comparison. The clinical and utility data were taken from published studies. The cost data were estimated from local charge data and current Chinese practices. Sensitivity analyses were used to explore the impact of uncertainty regarding the results. The impact of t